版本:
中国

BRIEF-Aurinia completes licensing deal with Merck Animal Health

April 17 Aurinia Pharmaceuticals Inc-

* Aurinia completes licensing deal with Merck Animal Health for its nanomicellar formulation of voclosporin for the treatment of canine dry eye syndrome

* Aurinia Pharma-signed agreement granting merck animal health worldwide rights to develop, commercialize co's nanomicellar voclosporin ophthalmic solution

* Aurinia Pharma-under deal, co will receive upfront payment, is eligible to receive further payments based on certain development and sales milestones

* Aurinia Pharmaceuticals Inc- under deal, aurinia will receive royalties based on global product sales

* Aurinia Pharma- under deal merck animal health to be responsible for remaining clinical development, commercialization of vos for use in animal health field

* Aurinia pharmaceuticals inc- under deal aurinia retains all human health rights related to vos Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐